ActoGeniX
A biopharmaceutical company, focused on the development and commercialization of a new generation of biological drugs.
Launch date
Employees
Market cap
-
Enterprise valuation
$60m (Public information from Feb 2015)
Company register number 0882.251.820
Ghent East Flanders (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 16.0m | 7.4m | 9.7m | 11.0m | 5.9m | 8.3m | 6.1m |
| % growth | 92 % | (54 %) | 31 % | 14 % | (46 %) | 41 % | (27 %) |
| EBITDA | 9.3m | (1.9m) | (2.0m) | (2.2m) | (<1m) | <1m | <1m |
| % EBITDA margin | 58 % | (25 %) | (21 %) | (21 %) | (16 %) | 11 % | 2 % |
| Profit | 9.0m | (3.1m) | (2.5m) | (2.3m) | (2.2m) | <1m | <1m |
| % profit margin | 56 % | (41 %) | (26 %) | (21 %) | (38 %) | 11 % | 13 % |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
€20.0m | - | ||
| N/A | $4.2m | Grant | |
* | $17.4m | Growth Equity VC | |
$60.0m Valuation: $60.0m | Acquisition | ||
| Total Funding | $43.6m | ||